B
Bull
Bull · 25%ENGN
$4.68
Precio del escenario
$1.825
-0.081 (-4.45%)Al cierre
Loading chart…
- High
- 1.910
- Open
- 1.910
- VWAP
- 1.85
- Vol
- 447.14K
- Mkt Cap
- —
- Low
- 1.810
- Amount
- 826.46K
- EV/EBITDA, TTM
- 0.00
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
AI analysis of enGene Therapeutics Inc (ENGN)
holdenGene Holdings Inc is not a good buy right now due to significant financial losses and analyst downgrades. The current price is $1.825, and the company reported a net loss of $30.23 million for Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability and growth potential.
Métricas de valoración
The current forward P/E ratio for enGene Therapeutics Inc (ENGN) is 0.00, compared to its 5-year average forward P/E of -3.05.
Alphio AI Price Scenarios for ENGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ENGN
Cronología de eventos
Noticias
8.506-19NASDAQ.COMBiotech Sector Sees FDA Approvals and Layoffs
9.506-16NASDAQ.COMenGene Reports Wider Q2 Loss Amid Clinical Updates
9.506-15seekingalphaenGene Holdings Reports Strong Q2 Earnings and Financial Position
7.006-04PRnewswirePomerantz Investigates enGene for Securities Fraud Claims
7.006-02GlobenewswirePomerantz LLP Investigates Securities Fraud Claims Against enGene Therapeutics
ENGN FAQ — answered by Alphio AI
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA). It operates in the Healthcare sector.
enGene Holdings Inc is not a good buy right now due to significant financial losses and analyst downgrades. The current price is $1.825, and the company reported a net loss of $30.23 million for Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability and growth potential.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.